Nobilis Therapeutics
  • Home
  • Company
    • About
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • NBTX-001
    • Science behind NBTX-001
    • Clinical Development Program
    • Intellectual property
  • Inhalation Devices
    • Nobilis™ Device
    • Zephyrus™ Device
  • Contact Us
Select Page

Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment

by nobilistx | Mar 8, 2016 | Uncategorized | 0 comments

http://www.marketwired.com/press-release/nobilis-therapeutics-signs-exclusive-license-agreement-with-harvard-university-ptsd-2109502.htm

Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment

Submit a Comment Cancel reply

You must be logged in to post a comment.

News

  • Nobilis Therapeutics Receives a Notice of Allowance from USPTO for a Patent Covering Treatments of Rheumatologic Disorders with Noble Gases March 14, 2018
  • Nobilis Therapeutics issues a press release after a productive meeting with the House of Representatives Committee on Veterans’ Affairs. February 23, 2018
  • On February 21st Nobilis Therapeutics will present its PTSD clinical program to the US Congress February 18, 2018
  • Nobilis Therapeutics will present its clinical study of the use of NBTX-001 in patients with Panic Disorder at the ADAA annual meeting January 31, 2018
  • Nobilis Therapeutics to attend J.P.Morgan’s 36th Annual Healthcare Conference December 20, 2017

Recent Posts

  • Nobilis Therapeutics Receives a Notice of Allowance from USPTO for a Patent Covering Treatments of Rheumatologic Disorders with Noble Gases
  • Nobilis Therapeutics issues a press release after a productive meeting with the House of Representatives Committee on Veterans’ Affairs.
  • On February 21st Nobilis Therapeutics will present its PTSD clinical program to the US Congress
  • Nobilis Therapeutics will present its clinical study of the use of NBTX-001 in patients with Panic Disorder at the ADAA annual meeting
  • Nobilis Therapeutics to attend J.P.Morgan’s 36th Annual Healthcare Conference

Recent Comments

    Archives

    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • October 2017
    • June 2017
    • May 2017
    • April 2016
    • March 2016
    • January 2016

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • RSS

    Designed by GO | Powered by GOs